Compare DXPE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXPE | AUPH |
|---|---|---|
| Founded | 1908 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1998 | 2014 |
| Metric | DXPE | AUPH |
|---|---|---|
| Price | $155.88 | $15.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $154.00 | $17.25 |
| AVG Volume (30 Days) | 188.4K | ★ 979.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.25 | ★ 5075.00 |
| EPS | ★ 1.22 | 0.25 |
| Revenue | ★ $1,247,043,000.00 | $283,055,000.00 |
| Revenue This Year | $9.31 | $17.54 |
| Revenue Next Year | $7.85 | $15.74 |
| P/E Ratio | ★ $28.10 | $60.70 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $75.58 | $7.29 |
| 52 Week High | $183.91 | $16.88 |
| Indicator | DXPE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 46.57 |
| Support Level | $107.83 | $14.56 |
| Resistance Level | $171.70 | $16.39 |
| Average True Range (ATR) | 8.70 | 0.67 |
| MACD | -1.67 | -0.11 |
| Stochastic Oscillator | 31.31 | 37.04 |
DXP Enterprises Inc is engaged in the business of distributing maintenance, repair and operating (MRO) products, equipment and service to customers in various end markets, including general industrial, energy, food & beverage, chemical, transportation, water and wastewater. The company operates through three business segments: Service Centers, Innovative Pumping Solutions and Supply Chain Services. The majority of revenue is derived from the Service Centers segment, which provides a wide range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products and safety services categories. Geographically, it generates the maximum revenue from the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.